Genomic and clinical characterization of early T-cell precursor lymphoblastic lymphoma. Read more about Genomic and clinical characterization of early T-cell precursor lymphoblastic lymphoma.
Transplant-associated thrombotic microangiopathy in pediatric patients: pre-HSCT risk stratification and prophylaxis. Read more about Transplant-associated thrombotic microangiopathy in pediatric patients: pre-HSCT risk stratification and prophylaxis.
Single-cell DNA sequencing reveals complex mechanisms of resistance to quizartinib. Read more about Single-cell DNA sequencing reveals complex mechanisms of resistance to quizartinib.
Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia. Read more about Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia.
A pragmatic multi-institutional approach to understanding transplant-associated thrombotic microangiopathy after stem cell transplant. Read more about A pragmatic multi-institutional approach to understanding transplant-associated thrombotic microangiopathy after stem cell transplant.
Early antibiotic use is associated with CMV risk and outcomes following allogeneic hematopoietic cell transplantation. Read more about Early antibiotic use is associated with CMV risk and outcomes following allogeneic hematopoietic cell transplantation.
Reduced immunogenicity of the adjuvanted recombinant zoster vaccine after hematopoietic cell transplant: a pilot study. Read more about Reduced immunogenicity of the adjuvanted recombinant zoster vaccine after hematopoietic cell transplant: a pilot study.
Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma. Read more about Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma.
Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. Read more about Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report.
CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma. Read more about CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.
